Compugen Ltd.
NASDAQ:CGENBiotechnology
Healthcare
$1.96 +0.50%
+$0.01 today
- Market cap
- $185.66M
- Beta
- 2.74
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.37
52W Low $1.30High $3.24
Volume 0.15M
Average 0.48M
Income Statement
Follow revenue through to earnings.
Revenue
$72.76M
FY 2025 · Annual
+161.1% YoYOperating Income
$31.33M
FY 2025 · Annual
Net Income
$35.34M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6M | 7.5M | 33.46M | 27.86M | 72.76M |
| Cost of Revenue | 680K | 975K | 2M | 7.93M | 9.25M |
| Gross Profit | 5.32M | 6.53M | 31.46M | 19.93M | 63.51M |
| Gross Margin | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| Research & Development | 28.69M | 30.65M | 34.47M | 24.81M | 22.76M |
| Selling, General & Admin | 11.7M | 11.25M | 9.98M | 10.02M | 9.43M |
| Operating Expenses | 40.39M | 41.9M | 44.45M | 34.83M | 32.19M |
| Depreciation & Amortization | 461K | 482K | 476K | 486K | 475K |
| EBITDA | (33.72M) | (33.13M) | (9.28M) | (9.19M) | 35.87M |
| EBITDA Margin | -562.0% | -441.7% | -27.7% | -33.0% | 49.3% |
| Operating Income | (35.07M) | (35.37M) | (12.99M) | (14.89M) | 31.33M |
| Operating Margin | -584.6% | -471.7% | -38.8% | -53.4% | 43.1% |
| Interest Income | 894K | 1.44M | 3.24M | 5.24M | 4.41M |
| Interest Expense | 25K | 27K | 31K | 34K | 0 |
| Other Income / Expenses | 871K | 1.74M | 3.21M | 5.18M | 4.07M |
| Income Before Tax | (34.2M) | (33.64M) | (9.78M) | (9.71M) | 35.4M |
| Pre-Tax Margin | -570.0% | -448.5% | -29.2% | -34.8% | 48.6% |
| Income Tax Expense | 0 | 58K | 8.97M | 4.52M | 54K |
| Net Income | (34.2M) | (33.69M) | (18.75M) | (14.23M) | 35.34M |
| Net Margin | -570.0% | -449.3% | -56.1% | -51.1% | 48.6% |
| EPS (Basic) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 |
| EPS (Diluted) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 |
| 84.2M | 86.56M | 87.63M | 89.53M | 93.43M | |
| 84.2M | 86.56M | 87.63M | 89.53M | 93.82M |
CGEN Earnings Waterfall · TTM
NASDAQ:CGEN · Revenue to Net Income
Key Ratios
EPS$0.37
Gross Margin22.8%
Net Margin-305.3%
P/E Ratio-4.1
P/S Ratio75.0
Analysis
$72.7M of revenue converted into $34.9M of net income for the selected period. Gross margin is 22.8% and net margin is -305.3%, showing how much revenue survives after costs and taxes. EPS is $0.37, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 9, 2026 | |
| 6-K | 6-K filing | Sep 10, 2026 | |
| 6-K | 6-K filing | Aug 3, 2026 | |
| 6-K | 6-K filing | Aug 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 30, 2026 |
How much revenue does CGEN generate?
Compugen Ltd. (CGEN) reported $72.76M of revenue in fiscal 2025.
Is CGEN profitable?
Compugen Ltd. (CGEN) reported $35.34M of net income, with a net margin of 48.6%.
Continue the stock analysis
Jump to another research area for this company.